Oak Ridge Investments LLC Cuts Holdings in Glaukos Corporation $GKOS

Oak Ridge Investments LLC cut its position in shares of Glaukos Corporation (NYSE:GKOS) by 3.6% during the 2nd quarter, Holdings Channel reports. The firm owned 10,695 shares of the medical instruments supplier’s stock after selling 402 shares during the quarter. Oak Ridge Investments LLC’s holdings in Glaukos were worth $1,105,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Inspire Investing LLC boosted its holdings in Glaukos by 17.2% during the second quarter. Inspire Investing LLC now owns 4,638 shares of the medical instruments supplier’s stock worth $479,000 after purchasing an additional 680 shares during the last quarter. Blair William & Co. IL boosted its holdings in Glaukos by 1.1% during the second quarter. Blair William & Co. IL now owns 47,250 shares of the medical instruments supplier’s stock worth $4,880,000 after purchasing an additional 518 shares during the last quarter. US Bancorp DE boosted its holdings in Glaukos by 12.6% during the second quarter. US Bancorp DE now owns 6,752 shares of the medical instruments supplier’s stock worth $697,000 after purchasing an additional 758 shares during the last quarter. Maryland State Retirement & Pension System boosted its holdings in Glaukos by 4.7% during the second quarter. Maryland State Retirement & Pension System now owns 16,793 shares of the medical instruments supplier’s stock worth $1,735,000 after purchasing an additional 751 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its holdings in Glaukos by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $2,758,000 after purchasing an additional 700 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Stock Performance

Shares of GKOS stock opened at $82.55 on Friday. The firm has a market cap of $4.73 billion, a price-to-earnings ratio of -50.03 and a beta of 0.76. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. Glaukos Corporation has a 52 week low of $77.10 and a 52 week high of $163.71. The firm’s 50-day simple moving average is $87.95 and its two-hundred day simple moving average is $92.69.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. During the same quarter in the previous year, the firm posted ($0.52) earnings per share. The company’s quarterly revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on GKOS shares. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a report on Thursday, July 31st. BTIG Research restated a “buy” rating and set a $118.00 price target on shares of Glaukos in a report on Wednesday, September 10th. The Goldman Sachs Group initiated coverage on shares of Glaukos in a research report on Wednesday, October 1st. They issued a “buy” rating and a $103.00 price objective on the stock. Zacks Research lowered shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. Finally, Mizuho set a $130.00 price objective on shares of Glaukos in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.00.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.